Every claim we hold, and how far we can stand behind it.
142 claims across 39 products. 30% are confirmed against the source text by the evidence gate; 39% come from a class with no vendor interest. Everything below is browsable, filterable, and available as JSON.
| Evidence class | Claims | Confirmed | What it can support |
|---|---|---|---|
| Peer-reviewed study | 19 | 5 | Independent review before publication. The only class that survives a sceptical committee unaided. |
| Regulatory filing | 4 | 0 | A statement made to a regulator, where being wrong has consequences. |
| Independent report | 32 | 9 | Analysis by someone with no stake in the sale. |
| Customer case | 4 | 3 | A real deployment, but selected and framed by someone with an interest. |
| Press release | 63 | 23 | The vendor's own announcement. Useful for dates and facts, not for outcomes. |
| Vendor page | 20 | 2 | Marketing copy. Establishes what is claimed, never that it is true. |
Showing 1 of 1 matching claims (142 in the full corpus) · 0% of this selection is confirmed · clear filters
CERTAIN study (European Heart Journal - Cardiovascular Imaging, 2024): in 750 consecutive patients at 5 expert CCTA sites, Cleerly AI-QCT analysis improved physicians' confidence two- to five-fold at every step of the care pathway, changed diagnosis or management in 57.1% (428) of patients (P<0.001), and reduced the need for downstream non-invasive and invasive testing by 37.1% (P<0.001) versus conventional visual CCTA interpretation.
Provenance
- Claim ID
- clm_a7d0185737df3457a3b3
- Version
- 1
- Workflow
- Imaging & Diagnostic AI
- Dimension
- evidence strength
- Retrieved
- 2026-08-27
- Reviewer
- healthit-gate-v1
- Source URL
- https://pmc.ncbi.nlm.nih.gov/articles/PMC11139521/